Overview of Bayer’s Operations in Mexico
The German pharmaceutical giant, Bayer, exports approximately $300 million worth of pharmaceutical products annually from its manufacturing plants in Mexico. These exports reach more than 30 markets, including the United States, Canada, Latin America, Europe, and the Middle East.
Key Export Destinations
- United States: Around 20% of Bayer’s Mexican exports are directed towards the US market.
- Canada, Latin America, Europe, and the Middle East: The remaining exports cater to these regions.
Notable Exported Products
Among the most exported products are over-the-counter medications such as Aspirin and Alka-Seltzer, which are manufactured at Bayer’s Mexican facilities.
Bayer’s Manufacturing Facilities in Mexico
Daniel Londero, Director of Bayer’s Pharmaceutical Division in Mexico, highlighted that one of the key manufacturing plants is located in Orizaba-Ixtaczoquitlán, Veracruz. This facility produces hormonal contraceptives exported throughout Latin America.
This plant is one of four worldwide dedicated to producing pharmaceutical active ingredients (APIs). It is the only one located outside Europe, supplying hormones or chemical precursors used in the production of contraceptives distributed globally.
Bayer also operates another plant in the State of Mexico, which manufactures over-the-counter medications for local consumption and export to the United States, Canada, and the Middle East.
Bayer’s Investment in Mexico
Bayer has announced a $3,000 million peso investment over the next five years to modernize and expand production capacity at its Mexican plants.
“Bayer has long decided to invest in Mexico, with plans not only for the short term but also medium and long term,” said Daniel Londero.
The decision to invest in Mexico is also driven by its strategic location, enabling product distribution to the United States, Latin America, and other global regions.
Mexico’s Attractiveness for Investment
With a GDP ranking of 15th globally and a population exceeding 130 million, Mexico presents an “ideal” investment location due to its large market and population size, according to Londero.
Bayer’s Advancements in Innovative Medicine
Bayer is entering a new phase of medicine, focusing on not just treating diseases but curing them through groundbreaking gene and cell therapies.
This year, Bayer initiated a Phase 3 clinical study using cell therapy for Parkinson’s disease treatment, affecting over 10 million people worldwide.
Key Questions and Answers
- What is the annual export value from Bayer’s Mexican plants? Approximately $300 million.
- Which markets receive these exports? Over 30 markets, including the US, Canada, Latin America, Europe, and the Middle East.
- What types of products are exported? Over-the-counter medications like Aspirin and Alka-Seltzer, along with hormonal contraceptives exported to Latin America.
- How many manufacturing plants does Bayer operate in Mexico? Two, with one located in Veracruz and another in the State of Mexico.
- What is Bayer’s planned investment in its Mexican plants? A $3,000 million peso investment over the next five years.
- Why is Mexico an attractive investment location for Bayer? Its strategic location, large market, and population size make it an ideal investment destination.
- What innovative medicine approaches is Bayer focusing on? Gene and cell therapies aimed at curing diseases, including a recent Parkinson’s disease study.
